GENE ONLINE|News &
Opinion
Blog

2018-03-06| Asia-PacificIPO

China’s Tasly, TCM Pharma, Plans to List in $1 Billion Hong Kong IPO

by GeneOnline
Share To

China’s Tasly Pharmaceutical Group, a traditional Chinese medicine pharmaceutical company, plans to list its biopharma unit in Hong Kong to raise about $1 billion.

By Joanne Shih

As Hong Kong Exchanges and Clearing (HKEX), the stock exchange operator of the city, is easing up its listing rules to attract early-stage drug developers, this Tianjin-based pharmaceutical company, Tasly, announced to aim at Hong Kong IPO and to list its biopharma branch, Shanghai Tasly Pharmaceutical, in the second half of 2018.

Tasly Pharmaceutical International was incorporated in 1994, and has opened overseas branches and representative offices in 21 nations or regions and 4 chain traditional Chinese medicine clinics in 4 countries after more than ten years of operation. Tasly Holding Group currently has 50-odd branches and subsidiaries and 15,000 employees, and has registered more than 50 products in over 40 countries as adjuvant, health product and functional food, according to its website. On the other hand, Shanghai Tasly was founded in 2001 in China, and the company lunched one drug for treating blood-clot induced heart attacks in 2012.

Sources from Tasly Pharmaceutical Group also indicated that the Shanghai Tasly is considering a pre-IPO fundraising, although the scale has not been confirmed yet. Nonetheless, the people with knowledge of this matter declined to release further details as they claimed that they were not authorized to speak with the media.

Reference
https://www.taslyint.com/index.php
https://www.reuters.com/article/us-tasly-pharma-hongkong-ipo/chinas-tasly-to-list-biotech-arm-in-1-billion-hong-kong-ipo-sources-idUSKBN1GH0JI

Image Source
https://www.reuters.com/article/us-tasly-pharma-hongkong-ipo/chinas-tasly-to-list-biotech-arm-in-1-billion-hong-kong-ipo-sources-idUSKBN1GH0JI

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Pioneering Partnership: Africa CDC and China CDC Elevate Public Health Initiatives
2023-11-20
Biotheus Collaborates with BioNTech for Global Development of Cancer Therapy
2023-11-08
LATEST
BIODND – An AI-Powered Database That Breaks New Ground in Life Science Business Development
2023-11-29
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top